Skip to main content
SpringerLink
Log in

Prise en charge thérapeutique des cancers de prostate

  • Chapter
Thérapeutique du cancer

  • 759 Accesses

Résumé

L’évolution de l’incidence des cancers de prostate dépend de l’impact du dépistage individuel par dosage du PSA (Prostate Specific Antigen). L’utilisation intensive du PSA aux États-Unis a provoqué un doublement des taux d’incidence en cinq ans avant qu’une baisse brutale ne survienne quand le taux a atteint 140 cas/100 000 hommes.

Membres du CCAFU : Salomon L, Azria D, Bastide C, Beuzeboc P, Cormier L, Cornud F, Eiss D, Eschwège P, Gaschignard N, Hennequin C, Molinié V, Mongiat Artus P, Moreau JL, Péneau M, Peyromaure M, Ravery V, Rebillard X, Richaud P, Rischmann P, Rozet F, Staerman F, Villers A, Soulié M.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. Salomon L, Azria D, Bastide C et al. membres du CCAFU (2010) Recommandations 2010. Cancer de prostate. Prog Urol 20Suppl 4: S217–S251

    Article  PubMed  Google Scholar 

  2. Ficarra V, Novara G, Artibani W et al. (2009) Retropubic, laparoscopic, and robot-assisted radical prostatectomy: a systematic review and cumulative analysis of comparative studies. Eur Urol 55: 1037–1063

    Article  PubMed  Google Scholar 

  3. Marien T, Sankin A, Lepor H (2009) Factors predicting preservation of erectile function in men undergoing open radical retropubic prostatectomy. J Urol 181: 1817–1822

    Article  PubMed  Google Scholar 

  4. Ayyathurai R, Manoharan M, Nieder AM et al. (2008) Factors affecting erectile function after radical retropubic prostatectomy: results from 1620 consecutive patients. BJU Int 101: 833–836

    Article  PubMed  Google Scholar 

  5. Simmons MN, Stephenson AJ, Klein EA (2007) Natural history of biochemical recurrence after radical prostatectomy: risk assessment for secondary therapy. Eur Urol 51: 1175–1184

    Article  PubMed  Google Scholar 

  6. Soulie M, Beuzeboc P, Cornud F. et al. (2007) Comité de Cancérologie de l’Association Française d’Urologie. Recommandations 2007 en onco-urologie. Cancer de la prostate. Prog Urol 17: 1157–1230

    Article  Google Scholar 

  7. Messing EM, Manola J, Yao J et al. (2006) Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 7: 472–429

    Article  PubMed  CAS  Google Scholar 

  8. Akakura K et al. Japanese Study Group for Locally Advanced Prostate Cancer (2006) A randomized trial comparing radical prostatectomy plus endocrine therapy versus external beam radiotherapy plus endocrine therapy for locally advanced prostate cancer: results at median follow-up of 102 months. Jpn J Clin Oncol 36: 789–793

    Article  PubMed  Google Scholar 

  9. Ward JF, Sebo TJ, Blute ML, Zincke H (2005) Salvage surgery for radiorecurrent prostate cancer: contemporary outcomes. J Urol 173: 1156–1160

    Article  PubMed  Google Scholar 

  10. Bianco FJ JR, Scardino PT, Stephenson AJ et al. (2005) Long-term oncologic results of salvage radical prostatectomy for locally recurrent prostate cancer after radiotherapy. Int J Radiat Oncol Biol Phys 62: 448–453

    Article  PubMed  Google Scholar 

  11. Peeters ST, Heemsbergen WD, Koper PC et al. (2006) Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol 24: 1990–1996

    Article  PubMed  Google Scholar 

  12. Pollack A, Zagars GK, Starkschall G et al. (2002) Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 53: 1097–1105

    Article  PubMed  Google Scholar 

  13. Zietman AL, Desilvio ML, Slater JD et al. (2005) Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA 294: 1233–1239

    Article  PubMed  CAS  Google Scholar 

  14. Roach M 3rd, Desilvio M, Lawton C et al. (2003) Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413. J Clin Oncol 21: 1904–1911

    Article  PubMed  Google Scholar 

  15. Pommier P, Chabaud S, Lagrange JL, et al. (2007) Is there a role for pelvic irradiation in localized prostate adenocarcinoma ? Preliminary results of GETUG-01. J Clin Oncol 25: 5366–5373

    Article  PubMed  Google Scholar 

  16. Roach M III, Bae K, Speight J et al. (2008) Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. J Clin Oncol 26: 585–591

    Article  PubMed  Google Scholar 

  17. Denham JW, Steigler A, Lamb DS et al. (2005) Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial. Lancet Oncol 6: 841–850

    Article  PubMed  CAS  Google Scholar 

  18. Crook J, Ludgate C, Malone S et al. (2004) Report of a multicenter Canadian phase III randomized trial of 3 months vs. 8 months neoadjuvant androgen deprivation before standard-dose radiotherapy for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 60: 15–23

    Article  PubMed  Google Scholar 

  19. d’Amico AV, Manola J, Loffredo M et al. (2004) 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA 292: 821–827

    Article  PubMed  Google Scholar 

  20. d’Amico AV, Chen MH, Renshaw AA et al. (2008) Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. JAMA 299: 289–295

    Article  PubMed  Google Scholar 

  21. Pilepich MV, Winter K, John MJ et al. (2001) Phase III radiation therapy oncology group (RTOG) trial 86–10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 50: 1243–1252

    Article  PubMed  CAS  Google Scholar 

  22. Kumar S, Shelley M, Harrison C et al. (2006) Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer. Cochrane Database Syst Rev CD006019

    Google Scholar 

  23. Pilepich MV, Winter K, Lawton CA et al. (2005) Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma—long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 61:1285–1290

    Article  PubMed  CAS  Google Scholar 

  24. Hanks GE, Pajak TF, Porter A et al. (2003) Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol 21: 3972–3978

    Article  PubMed  CAS  Google Scholar 

  25. Horwitz EM, Bae K, Hanks GE et al. (2008) Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol 26: 2497–2504

    Article  PubMed  CAS  Google Scholar 

  26. Bolla M, Collette L, Blank L et al. (2002) Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 360: 103–106

    Article  PubMed  CAS  Google Scholar 

  27. Bolla M, De Reijke TM, Van Tienhoven G et al. (2009) Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med 360: 2516–2527

    Article  PubMed  CAS  Google Scholar 

  28. Hartsell WF, Scott CB, Bruner DW et al. (2005) Randomized trial of shortversus long-course radiotherapy for palliation of painful bone metastases. J Natl Cancer Inst 97: 798–804

    Article  PubMed  Google Scholar 

  29. Guzzo TJ, Levin BM, Lee R et al. (2008) Relationship of biochemical outcome to percentage of positive biopsies in men with clinically localized prostate cancer treated with permanent interstitial brachytherapy. Urology 71: 723–727

    Article  PubMed  Google Scholar 

  30. Hinnen KA, Battermann JJ, Van Roermund JG et al. (2010) Long-term biochemical and survival outcome of 921 patients treated with I-125 permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 76: 1433–1438

    Article  PubMed  Google Scholar 

  31. Taira AV, Merrick GS, Galbreath RW et al. (2010) Natural history of clinically staged low-and intermediate-risk prostate cancer treated with monotherapeutic permanent interstitial brachytherapy. Int J Radiat Oncol Biol Phys 76: 349–354

    Article  PubMed  Google Scholar 

  32. Crouzet S, Rebillard X, Chevallier D et al. (2010) Multicentric oncologic outcomes of high intensity focused ultrasound for localized prostate cancer in 803 patients. Eur Urol 58: 559–566

    Article  PubMed  Google Scholar 

  33. Poissonnier L, Chapelon JY, Rouviere O et al. (2007) Control of prostate cancer by transrectal HIFU in 227 patients. Eur Urol 51: 381–387

    Article  PubMed  CAS  Google Scholar 

  34. Murat FJ, Poissonnier L, Rabilloud M et al. (2009) Mid-term results demonstrate salvage high-intensity focused ultrasound (HIFU) as an effective and acceptably morbid salvage treatment option for locally radiorecurrent prostate cancer. Eur Urol 55: 640–647

    Article  PubMed  Google Scholar 

  35. Nguyen PL, d’Amico AV, Lee AK, Suh WW (2007) Patient selection, cancer control, and complications after salvage local therapy for post radiation prostate-specific antigen failure a systematic review of the literature. Cancer 110: 1417–1428

    Article  PubMed  Google Scholar 

  36. Seidenfeld J, Samson DJ, Hasselblad V et al. (2000) Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis. Ann Intern Med 132: 566–577

    Article  PubMed  CAS  Google Scholar 

  37. Klotz L, Boccon-Gibod L, Shore ND et al. (2008) The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallelgroup phase III study in patients with prostate cancer. BJU Int 102: 1531–1538

    Article  PubMed  CAS  Google Scholar 

  38. Irani J, Salomon L, Oba R et al. (2010) Efficacy of venlafaxine, medroxyprogesterone acetate and cyproterone acetate for the treatment of vasomotor hot flushes in men taking gonadotrophin releasing hormone analogues for prostate cancer: a double blind randomised trial. Lancet Oncol 11: 147–154

    Article  PubMed  CAS  Google Scholar 

  39. Smith MR, Boyce SP, Moyneur E et al. (2006) Risk of clinical fractures after gonadotropin-releasing hormone agonist therapy for prostate cancer. J Urol 175: 136–139

    Article  PubMed  CAS  Google Scholar 

  40. Levine G, d’Amico A, Berger P et al. (2010) Androgen-deprivation therapy in prostate cancer and cardiovascular risk. Circulation 121: 1–8

    Article  Google Scholar 

  41. Iversen P (2002) Antiandrogen monotherapy: indications and results. Urology 60(Suppl 1): 64–71

    Article  PubMed  Google Scholar 

  42. McLeod DG, Iversen P, See WA et al. (2006) Casodex Early Prostate Cancer Trialists’ Group. Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer. BJU Int 97: 247–254

    Article  PubMed  CAS  Google Scholar 

  43. See WA, Tyrrell CJ. Casodex (2006) Early Prostate Cancer Trialists’ Group. The addition of bicalutamide 150 mg to radiotherapy significantly improves overall survival in men with locally advanced prostate cancer. J Cancer Res Clin Oncol 132(Suppl 1): S7–S16

    Article  PubMed  CAS  Google Scholar 

  44. Eisenberger MA, Blumenstein BA, Crawford ED et al. (1998) Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 339: 1036–1042

    Article  PubMed  CAS  Google Scholar 

  45. Calais Da Silva FE, Bono AV, Whelan P et al. (2009) Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group. Eur Urol 55: 1269–1277

    Article  PubMed  CAS  Google Scholar 

  46. Studer UE, Whelan P, Albrecht W et al. (2006) Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent:EORTC Traila 30891. J Clin Oncol 24: 1868–1876

    Article  PubMed  Google Scholar 

  47. Reid AH, Attard G, Danila DC et al. (2010) Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J Clin Oncol 28: 1489–1495

    Article  PubMed  CAS  Google Scholar 

  48. Danila DC, Morris MJ, De Bono JS et al. (2010) Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxeltreated castration-resistant prostate cancer. J Clin Oncol 28: 1496–1501

    Article  PubMed  CAS  Google Scholar 

  49. Tran C, Ouk S, Clegg NJ et al. (2009) Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer. Science 324: 787–790

    Article  PubMed  CAS  Google Scholar 

  50. Kantoff PW, Halabi S, Conaway M et al. (1999) Hydrocortisone with or without mitoxantrone in patients with hormone refractory prostate cancer: results of the Cancer and Leukemia Group B 9182 study (9182). J Clin Oncol 17: 2506–2513

    PubMed  CAS  Google Scholar 

  51. Tannock IF, Osoba D, Stockler MR et al. (1996) Chemotherapy with mitoxantrone plus prednisone and low dose prednisone in patients with hormonally resistant prostate cancer. J Clin Oncol 14: 1556–1564

    Google Scholar 

  52. Tannock IF, De Wit R, Berry WR et al. (2004) TAX 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351: 1502–1512

    Article  PubMed  CAS  Google Scholar 

  53. Petrylak DP, Tangen CM, Hussain MH et al. (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for Advanced refractory prostate cancer. N Engl J Med 351: 1513–1520

    Article  PubMed  CAS  Google Scholar 

  54. Fizazi K, Le Maitre A, Hudes G et al. (2007) Meta-analysis of Estramustine in Prostate Cancer (MECaP) Trialists’ Collaborative Group. Addition of estramustine to chemotherapy and survival of patients with castrationrefractory prostate cancer: a meta-analysis of individual patient data. Lancet Oncol 8: 994–1000

    Article  PubMed  CAS  Google Scholar 

  55. Eymard JC, Oudard S, Gravis G et al. (2010) Docetaxel reintroduction in patients with metastatic hormone-refractory, docetaxel-sensitive, prostate cancer: A retrospective multicenter study (TRIADE). BJU International 106: 974–978

    Article  PubMed  CAS  Google Scholar 

  56. de Bono JS, Oudard S, Ozguroglu M et al. (2010) TROPIC Investigators. Prednisone plus cabazitaxel or mitoxantrone for metastaticcastration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 376: 1147–1154

    Article  PubMed  Google Scholar 

  57. Saad F, Gleason DM, Murray R et al. (2004) Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 96: 879–882

    Article  PubMed  CAS  Google Scholar 

  58. Fizazi K, Carducci A, Smith MR et al. (2010) A randomized phas III trial of denosumab versus zoledronic acid in patients with bone metastases from castration-resistant prostate cancer. ASCO, Abstr 4507

    Google Scholar 

  59. d’Amico AV, Whittington R, Malkowicz SB et al. (2000) Clinical utility of the percentage of positive prostate biopsies in defining biochemical outcome after radical prostatectomy for patients with clinically localized prostate cancer. J Clin Oncol 18: 1164–1672

    PubMed  Google Scholar 

  60. d’Amico AV, Chen MH, Roehl KA, Catalona WJ (2004) Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 351: 125–135

    Article  PubMed  Google Scholar 

  61. Peeters ST, Heemsbergen WD, Koper PC et al. (2006) Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol 24: 1990–1996

    Article  PubMed  Google Scholar 

  62. Pollack A, Zagars G, Starkschall G. et al. (2002) Prostate cancer radiation dose response: results of the M.D. Anderson Phase III randomized trial. Int. J. Radiat Oncol Biol Phys 53: 1097–1105

    Article  PubMed  Google Scholar 

  63. Sathya JR, Davis IR, Julian JA et al. (2005) Randomized trial comparing iridium implant plus external-beam radiation therapy with external-beam radiation therapy alone in node-negative locally advanced cancer of the prostate. J Clin Oncol 23: 1192–1199

    Article  PubMed  Google Scholar 

  64. Zietman AL, Desilvio ML, Slater JD et al. (2005) Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA 294: 1233–1239

    Article  PubMed  CAS  Google Scholar 

  65. Zelefsky MJ, Yamada Y, Fuks Z et al. (2008) A. Long-term results of conformal radiotherapy for prostate cancer: impact of dose escalation on biochemical tumor control and distant metastases-free survival outcomes. Int J Radiat Oncol Biol Phys 71: 1028–1033

    Article  PubMed  Google Scholar 

  66. d’Amico A, Manola J, Loffredo M et al. (2004) 6-month suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer. JAMA 292: 821–827

    Article  PubMed  Google Scholar 

  67. d’Amico AV, Chen MH, Renshaw AA et al. (2008) Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. JAMA 299: 289–295

    Article  PubMed  Google Scholar 

  68. Pilepich MV, Winter K, Lawton CA et al. (2005) Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma — long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 61: 1285–1290

    Article  PubMed  CAS  Google Scholar 

  69. Bolla M, Collette L, Blank L et al. (2003) Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase IIII randomised trial. Lancet 360: 103–108

    Article  Google Scholar 

  70. Widmark A, Klepp O, Solberg A et al. (2009) Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet 373: 301–308

    Article  PubMed  CAS  Google Scholar 

  71. Bolla M, De Reijke TM, Van Tienhoven G et al. (2009) Duration of androgen suppression in the treatment of prostate cancer N Engl J Med 360: 2516–2527

    Article  PubMed  CAS  Google Scholar 

  72. Warde PR, Mason MD, Sydes MR et al. (2010) Intergroup randomized phase III study of androgen deprivation therapy + radiation therapy in locally Advanced prostate cancer (NCIC-CTG, SWOG, MRC-UK, INT:T94-0110;NCT00002633), ASCO 2010, Abstr 4504

    Google Scholar 

  73. Mottet N, Peneau M, Mazeron J et al. (2010) Impact of radiotherapy combined with androgen deprivation (ADT) versus ADT alone for local control in clinically locally Advanced prostate cancer. ASCO 2010, Abstr 4505

    Google Scholar 

  74. Sher HI, Sawyers CL (2005) Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signalling. J Clin Oncol 23: 8253–8261

    Article  Google Scholar 

  75. Montgomery RB, Mostaghel EA, Vessella R et al. (2008) Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res 68: 4447–4454

    Article  PubMed  CAS  Google Scholar 

  76. Kantoff PW, Higano CS, Shore ND et al. (2010) IMPACT Study Investigators. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363: 411–422

    Article  PubMed  CAS  Google Scholar 

  77. De Bono JS (2010) Abiraterone acetate significantly improved overall survival for patients with metatsatatic Advanced prostate cancer. ESMO 2010, Abs LBA 5

    Google Scholar 

  78. Fizazi K, Carducci A, Smith MR et al. (2010) A randomized phas III trial of denosumab versus zoledronic acid in patients with bone metastases from castration-resistant prostate cancer. ASCO 2010, Abstr 4507

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Service d’oncologie médicale, Institut Curie, 26 rue d’Ulm, Paris, 75005

    P. Beuzeboc

Authors
  1. P. Beuzeboc
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

CCAFU(Comité cancérologique de l’Association française d’urologie)

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer-Verlag France

About this chapter

Cite this chapter

Beuzeboc, P., CCAFU(Comité cancérologique de l’Association française d’urologie). (2011). Prise en charge thérapeutique des cancers de prostate. In: Thérapeutique du cancer. Springer, Paris. https://doi.org/10.1007/978-2-8178-0021-9_27

Download citation

  • DOI: https://doi.org/10.1007/978-2-8178-0021-9_27

  • Publisher Name: Springer, Paris

  • Print ISBN: 978-2-8178-0020-2

  • Online ISBN: 978-2-8178-0021-9

Publish with us

Policies and ethics

Search

Navigation